Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Shalom Hajag"'
Autor:
Dimitrios Karussis, Hagai Shor, Julia Yachnin, Naama Lanxner, Merav Amiel, Keren Baruch, Yael Keren-Zur, Ofra Haviv, Massimo Filippi, Panayiota Petrou, Shalom Hajag, Urania Vourka-Karussis, Adi Vaknin-Dembinsky, Salim Khoury, Oded Abramsky, Henri Atlan, Irun R Cohen, Rivka Abulafia-Lapid
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50478 (2012)
T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled.To evaluate the safety and efficacy of TCV in pro
Externí odkaz:
https://doaj.org/article/f9c593252a4541e598392ac03d903842
Autor:
Massimo Filippi, U. Vourka-Karussis, Panayiota Petrou, Keren Baruch, Julia Yachnin, Hagai Shor, Ofra Haviv, Adi Vaknin-Dembinsky, Rivka Abulafia-Lapid, Naama Lanxner, Henri Atlan, Dimitrios Karussis, Irun R. Cohen, Merav Amiel, Yael Keren-Zur, Shalom Hajag, Salim T. Khoury, Oded Abramsky
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50478 (2012)
PLoS ONE
PLoS ONE
Background T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. Aim To evaluate the safety and effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d74e4c7ffb46a1a7184ff1471208744
http://europepmc.org/articles/PMC3522721?pdf=render
http://europepmc.org/articles/PMC3522721?pdf=render